Exploration of the Relationship between Adipocytokines, Tradition Risk Markers, Nontraditional Risk Markers and Anthropometric Measurements in T2DM Patients — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Exploration of the Relationship between Adipocytokines, Tradition Risk Markers, Nontraditional Risk Markers and Anthropometric Measurements in T2DM Patients
Department of Biology, Faculty of Science, Qassim University, Buraydah, KSA
1 Department of Biology, Faculty of Science, Qassim University, Buraydah, KSA
Obesity is commonly associated with type 2 diabetes and vascular disease. Changes in body composition in the obese state lead to a dysregulation of secretion of adipocyte-secreted hormones known as adipokines. The current study aimed to assess the relative physiological correlation of adipocytokines with immunity in urban Saudi patients. The serum adipocytokine (leptin, adiponectin, resistin, visfatin and apelin), metabolic parameters (insulin, fasting glucose, HbA1c % (Glycated Hemoglobin) immunological indices (IgG, IgA, IgM and IgE) and complement factors (C3, C4) in different metabolic disorders states such as obesity and T2DM (Type 2 Diabetes Mellitus) were determined. A total 100 adult male subjects were enrolled including 30 healthy that served as a control, 25 Glucophage treated T2DM, 22 overweight (Body Mass Index (BMI) ≥ 25 - 29.99) and 23 obese (BMI ≥ 30) patients. The current results showed that serum adipocytokines status has altered in obesity and treated T2DM compared to healthy individuals. In addition to HbA1c %, serum visfatin was also the prominent biomarker adipokine in treated T2DM while leptin was the highest in obese (BMI ≥ 30). These metabolic disorders did not affect serum levels of the assessed immunity indices. Current knowledge suggests that adipokines provide potential therapeutic targets against type 2 diabetes and vascular disease. This study provides a strong association between adipocytokine and IR (Insulin Resistance). With the increasing epidemic of obesity and T2DM in Saudi Arabia, these adipocytokine markers that integrate metabolic and inflammatory signals may play important roles in the treatment and prevention of obesity and diabetes as well as planning of therapeutic strategies and the early detection of diabetes.
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S. and Lazar, M.A. (2001) The Hormone Resistin Links Obesity to Diabetes. Nature, 409, 307-312. http://dx.doi.org/10.1038/35053000
Goldstein, B.J. (2002) Insulin Resistance as the Core Defect in Type 2 Diabetes Mellitus. The American Journal of Cardiology, 90, 3G-10G. http://dx.doi.org/10.1016/S0002-9149(02)02553-5
Lempiainen, P., Mykkanen, L., Pyorala, K., Laakso, M. and Kuusisto, J. (1999) Insulin Resistance Syndrome Predicts Coronary Heart Disease Events in Elderly Nondiabetic Men. Circulation, 100, 123-128. http://dx.doi.org/10.1161/01.CIR.100.2.123
Mlinar, B., Marc, J., Janez, A. and Pfeifer, M. (2007) Molecular Mechanisms of Insulin Resistance and Associated Diseases. Clinica Chimica Acta, 375, 20-35. http://dx.doi.org/10.1016/j.cca.2006.07.005
Ingelsson, E., Arnlov, J., Lind, L. and Sundstrom, J. (2006) Metabolic Syndrome and Risk for Heart Failure in Middle-Aged Men. Heart, 92, 1409-1413. http://dx.doi.org/10.1136/hrt.2006.089011
Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., et al. (2002) The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-Aged Men. JAMA, 288, 2709-2716. http://dx.doi.org/10.1001/jama.288.21.2709
Kahn, S.E., Hull, R.L. and Utzschneider, K.M. (2006) Mechanisms Linking Obesity to Insulin Resistance and Type 2 Diabetes. Nature, 444, 840-846. http://dx.doi.org/10.1038/nature05482
Weiss, R., Dziura, J., Burgert, T.S., et al. (2004) Obesity and the Metabolic Syndrome in Children and Adolescents. The New England Journal of Medicine, 350, 2362-2374. http://dx.doi.org/10.1056/NEJMoa031049
Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y. and Walsh, K. (2003) Obesity, Adiponectin and Vascular Inflammatory Disease. Current Opinion in Lipidology, 14, 561-566. http://dx.doi.org/10.1097/00041433-200312000-00003
Koerner, A., Kratzsch, J. and Kiess, W. (2005) Adipocytokines: Leptin—The Classical, Resistin—The Controversical, Adiponectin—The Promising, and More to Come. Best Practice & Research Clinical Endocrinology & Metabolism, 19, 525-546. http://dx.doi.org/10.1016/j.beem.2005.07.008
Tilg, H. and Moschen, A.R. (2006) Adipocytokines: Mediators Linking Adipose Tissue, Inflammation and Immunity. Nature Reviews Immunology, 6, 772-783. http://dx.doi.org/10.1038/nri1937
Complement Factor
Matsuzawa, Y. (2005) Adipocytokines and Metabolic Syndrome. Seminars in Vascular Medicine, 5, 34-39. http://dx.doi.org/10.1055/s-2005-871744
Rabin, K.R., Kamari, Y., Avni, I., Grossman, E. and Sharabi, Y. (2005) Adiponectin: Linking the Metabolic Syndrome to Its Cardiovascular Consequences. Expert Review of Cardiovascular Therapy, 3, 465-471. http://dx.doi.org/10.1586/14779072.3.3.465
Guzik, T.J., Korbut, R. and Adamek-Guzik, T. (2003) Nitric Oxide and Superoxide in Inflammation and Immune Regulation. Journal of Physiology and Pharmacology, 54, 469-487.
Klaus, S. (2004) Adipose Tissue as a Regulator of Energy Balance. Current Drug Targets, 5, 241-250. http://dx.doi.org/10.2174/1389450043490523
Matsuzawa, Y. (2010) Adiponectin: A Key Player in Obesity Relate Disorders. Current Pharmaceutical Design, 16, 1896-1901. http://dx.doi.org/10.2174/138161210791208893
Falcao-Pires, I., Castro-Chaves, P., Miranda-Silva, D., Lourenco, A.P. and Leite-Moreira, A.F. (2012) Physiological, Pathological and Potential Therapeutic Roles of Adipokines. Drug Discovery Today, 17, 880-889. http://dx.doi.org/10.1016/j.drudis.2012.04.007
Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Hecht, R., Winters, D., Boone, T., et al. (1995) Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice. Science, 269, 540-543. http://dx.doi.org/10.1126/science.7624776
Lee, G.H., Proenca, R., Montez, J.M., Carroll, K.M., Darvishzadeh, J.G., Lee, J.I., et al. (1996) Abnormal Splicing of the Leptin Receptor in Diabetic Mice. Nature, 379, 632-635. http://dx.doi.org/10.1038/379632a0
Saladin, R., De Vos, P., Guerre-Millo, M., Leturque, A., Girard, J., Staels, B., et al. (1995) Transient Increase in Obese Gene Expression after Food Intake or Insulin Administration. Nature, 377, 527-529. http://dx.doi.org/10.1038/377527a0
Geffroy, S., De Vos, P., Staels, B., Duban, B., Auwerx, J. and de Martinville, B. (1995) Localization of the Human OB Gene (OBS) to Chromosome 7q32 by Fluorescence in Situ Hybridization. Genomics, 28, 603-604. http://dx.doi.org/10.1006/geno.1995.1201
Brzozowski, T., Konturek, P.C., Konturek, S.J., Brzozowska, I. and Pawlik, T. (2005) Role of Prostaglandins in Gastroprotection and Gastric Adaptation. Journal of Physiology and Pharmacology, 56, 33-55.
Nawrot-Porabka, K., Jaworek, J., Leja-Szpak, A., Palonek, M., Szklarczyk, J., Konturek, S.J., et al. (2004) Leptin Is Able to Stimulate Pancreatic Enzyme Secretion via Activation of Duodeno-Pancreatic Reflex and CCK Release. Journal of Physiology and Pharmacology, 55, 47-57.
Konturek, P.C., Brzozowski, T., Burnat, G., Kwiecien, S., Pawlik, T., Hahn, E.G., et al. (2004) Role of Brain-Gut Axis in Healing of Gastric Ulcers. Journal of Physiology and Pharmacology, 55, 179-192.
Konturek, S.J., Konturek, J.W., Pawlik, T. and Brzozowski, T. (2004) Brain-Gut Axis and Its Role in the Control of Food Intake. Journal of Physiology and Pharmacology, 55, 137-154.
Konturek, S.J., Pepera, J., Zabielski, K., Konturek, P.C., Pawlik, T., Szlachcic, A., et al. (2003) Brain-Gut Axis in Pancreatic Secretion and Appetite Control. Journal of Physiology and Pharmacology, 54, 293-317.
Farooqi, I.S., Matarese, G., Lord, G.M., Keogh, J.M., Lawrence, E., Agwu, C., et al. (2002) Beneficial Effects of Leptin on Obesity, T Cell Hyporesponsiveness, and Neuroendocrine/Metabolic Dysfunction of Human Congenital Leptin Deficiency. Journal of Clinical Investigation, 110, 1093-1103. http://dx.doi.org/10.1172/JCI0215693
Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H., Wareham, N.J., et al. (1997) Congenital Leptin Deficiency Is Associated with Severe Early-Onset Obesity in Humans. Nature, 387, 903-908. http://dx.doi.org/10.1038/43185
Zoladz, J.A., Konturek, S.J., Duda, K., Majerczak, J., Sliwowski, Z., Grandys, M., et al. (2005) Effect of Moderate Incremental Exercise, Performed in Fed and Fasted State on Cardio-Respiratory Variables and Leptin and Ghrelin Concentrations in Young Healthy Men. Journal of Physiology and Pharmacology, 56, 63-85.
Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., et al. (1996) Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. New England Journal of Medicine, 334, 292-295. http://dx.doi.org/10.1056/NEJM199602013340503
Kim, S., Whelan, J., Claycombe, K., Reath, D.B. and Moustaid-Moussa, N. (2002) Angiotensin II Increases Leptin Secretion by 3T3-L1 and Human Adipocytes via a Prostaglandin-Independent Mechanism. Journal of Nutrition, 132, 1135-1140.
Ran, J., Hirano, T., Fukui, T., Kageyama, H., Okada, K. and Adachi, M. (2006) Angiotensin II Infusion Decreases Plasma Adiponectin Level via Its Type 1 Receptor in Rats: An Implication for Hypertension-Related Insulin Resistance. Metabolism, 55, 478-488. http://dx.doi.org/10.1016/j.metabol.2005.10.009
Kaminski, T., Smolinska, N., Gajewska, A., Siawrys, G., Okrasa, S., Kochman, K., et al. (2006) Leptin and Long Form of Leptin Receptor Genes Expression in the Hypothalamus and Pituitary during the Luteal Phase and Early Pregnancy in Pigs. Journal of Physiology and Pharmacology, 57, 95-108.
Beltowski, J., Marciniak, A. and Wojcicka, G. (2004) Leptin Decreases Renal Medullary Na(+), K(+)-ATPase Activity through Phosphatidylinositol 3-Kinase Dependent Mechanism. Journal of Physiology and Pharmacology, 57, 391-407.
Jaworek, J., Bonior, J., Konturek, S.J., Bilski, J., Szlachcic, A. and Pawlik, W.W. (2003) Role of Leptin in the Control of Postprandial Pancreatic Enzyme Secretion. Journal of Physiology and Pharmacology, 57, 591-602.
Stallmeyer, B., Pfeilschifter, J. and Frank, S. (2001) Systemically and Topically Supplemented Leptin Fails to Reconstitute a Normal Angiogenic Response during Skin Repair in Diabetic ob/ob mice. Diabetologia, 44, 471-479. Http://Dx.Doi.Org/10.1007/S001250051645
Kougias, P., Chai, H., Lin, P.H., Yao, Q., Lumsden, A.B. and Chen, C. (2005) Effects of Adipocyte-Derived Cytokines on Endothelial Functions: Implication of Vascular Disease. Journal of Surgical Research, 126, 121-129. http://dx.doi.org/10.1016/j.jss.2004.12.023
Schwartz, M.W., Woods, S.C., Porte Jr., D., Seeley, R.J. and Baskin, D.G. (2000) Central Nervous System Control of Food Intake. Nature, 404, 661-671.
Friedman, J.M. and Halaas, J.L. (1998) Leptin and the Regulation of Body Weight in Mammals. Nature, 395, 763-770. http://dx.doi.org/10.1038/27376
Kaur, T. and Zhang, Z.F. (2005) Obesity, Breast Cancer and the Role of Adipocytokines. Asian Pacific Journal of Cancer Prevention, 6, 547-552.
Kubota, N., Terauchi, Y., Yamauchi, T., Kubota, T., Moroi, M., Matsui, J., et al. (2002) Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation. Journal of Biological Chemistry, 277, 25863-25866. http://dx.doi.org/10.1074/jbc.C200251200
Xu, A., Yin, S., Wong, L., Chan, K.W. and Lam, K.S. (2004) Adiponectin Ameliorates Dyslipidemia Induced by the Human Immunodeficiency Virus Protease Inhibitor Ritonavir in Mice. Endocrinology, 145, 487-494. http://dx.doi.org/10.1210/en.2003-1140
Yoon, M.J., Lee, G.Y., Chung, J.J., Ahn, Y.H., Hong, S.H. and Kim, J.B. (2006) Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator-Activated Receptor Alpha. Diabetes, 55, 2562-2570. http://dx.doi.org/10.2337/db05-1322
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., et al. (2003) Cloning of Adiponectin Receptors That Mediate Antidiabetic Metabolic Effects. Nature, 423, 762-769. http://dx.doi.org/10.1038/nature01705
Qi, Y., Takahashi, N., Hileman, S.M., Patel, H.R., Berg, A.H., Pajvani, U.B., Scherer, P.E. and Ahima, R.S. (2004) Adiponectin Acts in the Brain to Decrease Body Weight. Nature Medicine, 10, 524-529. http://dx.doi.org/10.1038/nm1029
Neumeier, M., Weigert, J., Schaffler, A., Wehrwein, G., Müller-Ladner, U., Scholmerich, J., et al. (2006) Different Effects of Adiponectin Isoforms in Human Monocytic Cells. Journal of Leukocyte Biology, 79, 803-808. http://dx.doi.org/10.1189/jlb.0905521
Wasim, H., Al-Daghri, N.M., Chetty, R., McTernan, P.G., Barnett, A.H. and Kumar, S. (2006) Relationship of Serum Adiponectin and Resistin to Glucose Intolerance and Fat Topography in South-Asians. Cardiovascular Diabetology, 5, 10. http://dx.doi.org/10.1186/1475-2840-5-10
Fain, J.N. (2006) Release of Interleukins and Other Inflammatory Cytokines by Human Adipose Tissue Is Enhanced in Obesity and Primarily Due to the Nonfat Cells. Vitamins & Hormones, 74, 443-477. http://dx.doi.org/10.1016/S0083-6729(06)74018-3
Bastard, J.P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., et al. (2006) Recent Advances in the Relationship between Obesity, Inflammation, and Insulin Resistance. European Cytokine Network, 17, 4-12.
Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., et al. (2005) Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin. Science, 307, 426-430. http://dx.doi.org/10.1126/science.1097243
Beltowski, J. (2006) Apelin and Visfatin: Unique “Beneficial” Adipokines Upregulated in Obesity? Medical Science Monitor, 12, RA112-RA119.
Haider, D.G., Schaller, G., Kapiotis, S., Maier, C., Luger, A. and Wolzt, M. (2006) The Release of the Adipocytokine Visfatin Is Regulated by Glucose and Insulin. Diabetologia, 49, 1909-1914. http://dx.doi.org/10.1007/s00125-006-0303-7
Revollo, J.R., Korner, A., Mills, K.F., Satoh, A., Wang, T., Garten, A., et al. (2007) Nampt/PBEF/Visfatin Regulates Insulin Secretion in Beta Cells as a Systemic NAD Biosynthetic Enzyme. Cell Metabolism, 6, 363-375.
Brown, J.E., Onyango, D.J., Ramanjaneya, M., Conner, A.C., Patel, S.T., Dunmore, S.J., et al. (2010) Visfatin Regulates Insulin Secretion, Insulin Receptor Signalling and mRNA Expression of Diabetes-Related Genes in Mouse Pancreatic Beta-Cells. Journal of Molecular Endocrinology, 44, 171-178. http://dx.doi.org/10.1677/JME-09-0071
Lan, J., Chen, X., Wang, S., Wanga, S., Zhang, X., Wu, K., et al. (2011) The Relationship between Visfatin and HOMA-IR in Hypertensive Patients, and the Effect of Antihypertensive Drugs on Visfatin and HOMA-IR in Hypertensive Patients with Insulin Resistance. Diabetes Research and Clinical Practice, 94, 71-76. http://dx.doi.org/10.1016/j.diabres.2011.05.039
Straburzynska-Lupa, A., Nowak, A., Pilaczynska-Szczesniak, L., Straburzyńska-Migaj, E., Romanowski, W., Karolkiewicz, J., et al. (2010) Visfatin, Resistin, hsCRP and Insulin Resistance in Relation to Abdominal Obesity in Women with Rheumatoid Arthritis. Clinical and Experimental Rheumatology, 28, 19-24.
Tatemoto, K., Takayama, K., Zou, M.X., Kumaki, I., Zhang, W., et al. (2001) The Novel Peptide Apelin Lowers Blood Pressure via a Nitric Oxide-Dependent Mechanism. Regulatory Peptides, 99, 87-92. http://dx.doi.org/10.1016/S0167-0115(01)00236-1
Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigne, C., et al. (2005) Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology, 146, 1764-1771. http://dx.doi.org/10.1210/en.2004-1427
El Messari, S., Iturrioz, X., Fassot, C., De Mota, N., Roesch, D., et al. (2004) Functional Dissociation of Apelin Receptor Signaling and Endocytosis: Implications for the Effects of Apelin on Arterial Blood Pressure. Journal of Neurochemistry, 90, 1290-1301. http://dx.doi.org/10.1111/j.1471-4159.2004.02591.x
Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., et al. (1998) Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor. Biochemical and Biophysical Research Communications, 251, 471-476. http://dx.doi.org/10.1006/bbrc.1998.9489
Castan-Laurell, I., Dray, C., Knauf, C., Kunduzova, O. and Valet, P. (2012) Apelin, a Promising Target for Type 2 Diabetes Treatment? Trends in Endocrinology and Metabolism, 23, 234-241. http://dx.doi.org/10.1016/j.tem.2012.02.005
Attané, C., Foussal, C., Le Gonidec, S., Benani, A., Daviaud, D., Wanecq, E., et al. (2012) Apelin Treatment Increases Complete Fatty Acid Oxidation, Mitochondrial Oxidative Capacity, and Biogenesis in Muscle of Insulin-Resistant Mice. Diabetes, 61, 310-320. http://dx.doi.org/10.2337/db11-0100
Yue, P., Jin, H., Xu, S., Aillaud, M., Deng, A.C., et al. (2011) Apelin Decreases Lipolysis via Gq, Gi, and AMPK-Dependent Mechanisms. Endocrinology, 152, 59-68. http://dx.doi.org/10.1210/en.2010-0576
Attané, C., Daviaud, D., Dray, C., Dusaulcy, R., Masseboeuf, M., Prévot, D., et al. (2011) Apelin Stimulates Glucose Uptake but Not Lipolysis in Human Adipose Tissue ex Vivo. Journal of Molecular Endocrinology, 46, 21-28. http://dx.doi.org/10.1677/JME-10-0105
Guo, L., Li, Q., Wang, W., Yu, P., Pan, H., Li, P., et al. (2009) Apelin Inhibits Insulin Secretion in Pancreatic Beta-Cells by Activation of PI3-Kinase-Phosphodiesterase 3B. Endocrine Research, 34, 142-154. http://dx.doi.org/10.3109/07435800903287079
Soriguer, F., Garrido-Sanchez, L., Garcia-Serrano, S., Garcia-Almeida, J.M., Garcia-Arnes, J., et al. (2009) Apelin Levels Are Increased in Morbidly Obese Subjects with Type 2 Diabetes Mellitus. Obesity Surgery, 19, 1574-1580. http://dx.doi.org/10.1007/s11695-009-9955-y
Dray, C., Debard, C., Jager, J., Disse, E., Daviaud, D., Martin, P., et al. (2010) Apelin and APJ Regulation in Adipose Tissue and Skeletal Muscle of Type 2 Diabetic Mice and Humans. American Journal of Physiology: Endocrinology and Metabolism, 298, E1161-E1169. http://dx.doi.org/10.1152/ajpendo.00598.2009
Erdem, G., Dogru, T., Tasci, I., Sonmez, A. and Tapan, S. (2008) Low Plasma Apelin Levels in Newly Diagnosed Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes, 116, 289-292. http://dx.doi.org/10.1055/s-2007-1004564
Zhang, Y., Shen, C., Li, X., Ren, G., Fan, X., Ren, F., et al. (2009) Low Plasma Apelin in Newly Diagnosed Type 2 Diabetes in Chinese People. Diabetes Care, 32, e150. http://dx.doi.org/10.2337/dc09-1146
Meral, C., Tascilar, E., Karademir, F., Tanju, I.A., Cekmez, F., Metin, O., et al. (2010) Elevated Plasma Levels of Apelin in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 23, 497-502. http://dx.doi.org/10.1515/jpem.2010.081
Telejko, B., Kuzmicki, M., Wawrusiewicz-Kurylonek, N., Szamatowicz, J., Nikolajuk, A., Zonenberg, A., et al. (2010) Plasma Apelin Levels and Apelin/APJ mRNA Expression in Patients with Gestational Diabetes Mellitus. Diabetes Research and Clinical Practice, 87, 176-183. http://dx.doi.org/10.1016/j.diabres.2009.10.018
Kouyama, K., Miyake, K., Zenibayashi, M., Hirota, Y., Teranishi, T., Tamori, Y., et al. (2007) Association of Serum MCP-1 Concentration and MCP-1 Polymorphism with Insulin Resistance in Japanese Individuals with Obese Type 2 Diabetes. Kobe Journal of Medical Sciences, 53, 345-354.
Suzuki, T., Imai, J., Yamada, T., Ishigaki, Y., Kaneko, K., Uno, K., et al. (2011) Interleukin-6 Enhances Glucose-Stimulated Insulin Secretion from Pancreatic Beta-Cells: Potential Involvement of the PLC-IP3-Dependent Pathway. Diabetes, 60, 537-547.
Besedovsky, H.O. and Del Rey, A. (2010) Interleukin-1 Resets Glucose Homeostasis at Central and Peripheral Levels: Relevance for Immunoregulation. Neuroimmunomodulation, 17, 139-141. http://dx.doi.org/10.1159/000258707
Enomoto, T., Ohashi, K., Shibata, R., Higuchi, A., Maruyama, S., Izumiya, Y., et al. (2011) Adipolin/C1qdc2/CTRP12 Protein Functions as an Adipokine That Improves Glucose Metabolism. Journal of Biological Chemistry, 286, 34552-34558.
Choi, J.H., Rhee, E.J., Kim, K.H., Woo, H.Y., Lee, W.Y. and Sung, K.C. (2011) Plasma Omentin-1 Levels Are Reduced in Non-Obese Women with Normal Glucose Tolerance and Polycystic Ovary Syndrome. European Journal of Endocrinology, 165, 789-796. http://dx.doi.org/10.1530/EJE-11-0375
Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D.M., et al. (2011) Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome. Diabetes, 60, 1917-1925. http://dx.doi.org/10.2337/db10-1707
El-Hazmi, M.A.F., Warsy, A.S., Al-Swailem, A.R., Al-Swailem, A.M. and Sulaimani, R. (1998) Diabetes Mellitus as a Health Problem in Saudi Arabia. Eastern Mediterranean Health Journal, 4, 58-67.
Al-Nozha, M.M., Al-Maatouq, M.A., Al-Mazrou, Y.Y., Al-Harthi, S.S., Arafah, M.R., Khalil, M.Z., Khan, N.B., Al-Khadra, A., Al-Marzouki, K., Nouh, M.S., Abdullah, M., Attas, O., Al-Shahid, M.S. and Al-Mobeireek, A. (2009) Diabetes Mellitus in Saudi Arabia. Saudi Medical Journal, 25, 1603-1610. King Fahd University of Petroleum & Minerals. http://www.kfupm.edu.sa
Gokalp, D., Bahceci, M., Ozmen, S., Arikan, S., Tuzcu, A. and Danis, R. (2008) Adipocyte Volumes and Levels of Adipokines in Diabetes and Obesity. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2, 253-258. http://dx.doi.org/10.1016/j.dsx.2008.07.001
Gualillo, O., González-Juanatey, J.R. and Lago, F. (2007) The Emerging Role of Adipokines as Mediators of Cardiovascular Function: Physiologic and Clinical Perspectives. Trends in Cardiovascular Medicine, 17, 275-283. http://dx.doi.org/10.1016/j.tcm.2007.09.005
Esteghamati, A., Alamdari, A., Zandieh, A., Elahi, S., Khalilzadeh, O., Nakhjavani, M. and Meysamie, A. (2011) Serum Visfatin Is Associated with Type 2 Diabetes Melitus Independent of Insulin Resistance and Obesity. Diabetes Research and Clinical Practice, 91, 154-158. http://dx.doi.org/10.1016/j.diabres.2010.11.003
Alghasham, A.A. and Barakat, Y.A. (2008) Serum Visfatin and Its Relation to Insulin Resistance and Inflammation in Type 2 Diabetic Patients with and without Macroangiopathy. Saudi Medical Journal, 29, 185-192.
Chang, Y.H., Chang, D.M., Lin, K.C., Shin, S.J. and Lee, Y.J. (2011) Visfatin in Overweight/Obesity, Type 2 Diabetes Mellitus, Insulin Resistance, Metabolic Syndrome and Cardiovascular Diseases: A Meta-Analysis and Systemic Review. Diabetes/Metabolism Research and Reviews, 27, 515-527. http://dx.doi.org/10.1002/dmrr.1201
El-Mesallamy, H.O., Kassem, D.H., El-Demerdash, E. and Amin, A.I. (2011) Vaspin and Visfatin/Nampt Are Interesting Interrelated Adipokines Playing a Role in the Pathogenesis of Type 2 Diabetes Mellitus. Metabolism, 60, 63-70. http://dx.doi.org/10.1016/j.metabol.2010.04.008
Sandeep, S., Velmurugan, K., Deepa, R. and Mohan, V. (2007) Serum Visfatin in Relation to Visceral Fat, Obesity, and Type 2 Diabetes Mellitus in Asian Indians. Metabolism, 56, 565-570. http://dx.doi.org/10.1016/j.metabol.2006.12.005
Shaker, O., El-Shehaby, A., Zakaria, A., Mostafa, N., Talaat, S., Katsiki, N. and Mikhailidis, D.P. (2011) Plasma Visfatin and Retinol Binding Protein-4 Levels in Patients with Type 2 Diabetes Mellitus and Their Relationship to Adiposity and Fatty Liver. Clinical Biochemistry, 44, 1457-1463. http://dx.doi.org/10.1016/j.clinbiochem.2011.08.1148
Meshkani, R. and Adeli, K. (2009) Hepatic Insulin Resistance, Metabolic Syndrome and Cardiovascular Disease. Clinical Biochemistry, 42, 1331-1346. http://dx.doi.org/10.1016/j.clinbiochem.2009.05.018
Zhu, J., Schott, M., Liu, R., Liu, C., Shen, B., Wang, Q., Mao, X., Xu, K., Wu, X., Schinner, S., Papewalis, C., Scherbaum, W.A. and Liu, C. (2008) Intensive Glycemic Control Lowers Plasma Visfatin Levels in Patients with Type 2 Diabetes. Hormone and Metabolic Research, 40, 801-805. http://dx.doi.org/10.1055/s-0028-1082040
Bloomgarden, Z.T. (2002) New Insights in Obesity. Diabetes Care, 25, 789-795. http://dx.doi.org/10.2337/diacare.25.4.789
Chen, M.P., Chung, F.M., Chang, D.M., Tsai, J.C.R., Huang, H.F., Shin, S.J., et al. (2006) Elevated Plasma Level of Visfatin/Pre-B Cell Colony-Enhancing Factor in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology & Metabolism, 91, 295-299. http://dx.doi.org/10.1210/jc.2005-1475
Miao-Pei, C., et al. (2006) Elevated Plasma Level of Visfatin/Pre-B Cell Colony Enhancing Factor in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology & Metabolism, 91, 295-299. http://dx.doi.org/10.1210/jc.2005-1475
Kaminska, A., Kopczyńska, E., Bronisz, A., Zmudzińska, M., Bieliński, M., Borkowska, A., et al. (2010) An Evaluation of Visfatin Levels in Obese Subjects. Endokrynologia Polska, 61, 169-173.
Tasci, I., Erdem, G., Ozgur, G., Tapan, S., Dogru, T., Genc, H., et al. (2009) LDL-Cholesterol Lowering Increases Plasma Apelin in Isolated Hypercholesterolemia. Atherosclerosis, 204, 222-228. http://dx.doi.org/10.1016/j.atherosclerosis.2008.08.030
Li, L., Yang, G., Li, Q., Tang, Y., Yang, M., Yang, H., et al. (2006) Changes and Relations of Circulating Visfatin, Apelin, and Resistin Levels in Normal, Impaired Glucose Tolerance, and Type 2 Diabetic Subjects. Experimental and Clinical Endocrinology & Diabetes, 114, 544-548. http://dx.doi.org/10.1055/s-2006-948309
Dray, C., Knauf, C., Daviaud, D., Waget, A., Boucher, J., et al. (2008) Apelin Stimulates Glucose Utilization in Normal and Obese Insulin-Resistant Mice. Cell Metabolism, 8, 437-445. http://dx.doi.org/10.1016/j.cmet.2008.10.003
Horiuchi, Y., Fujii, T., Kamimura, Y. and Kawashima, K. (2003) The Endogenous, Immunologically Active Peptide Apelin Inhibits Lymphocytic Cholinergic Activity during Immunological Responses. Journal of Neuroimmunology, 144, 46-52. http://dx.doi.org/10.1016/j.jneuroim.2003.08.029
Ranjana, S., Fisch, G., Teague, B., Tamborlane, W.V., Banyas, B., Allen, K., et al. (2002) Prevalence of Impaired Glucose Tolerance among Children and Adolescents with Marked Obesity. New England Journal of Medicine, 346, 802-810. http://dx.doi.org/10.1056/NEJMoa012578
Lu, H.L., Wang, H.W., Wen, Y., Zhang, M.X. and Lin, H.H. (2006) Roles of Adipocyte Derived Hormone Adiponectin and Resistin in Insulin Resistance of Type 2 Diabetes. World Journal of Gastroenterology, 12, 1747-1751.
Mojiminiyi, O.A. and Abdella, N.A. (2007) Associations of Resistin with Inflammation and Insulin Resistance in Patients with Type 2 Diabetes Mellitus. Scandinavian Journal of Clinical & Laboratory Investigation, 67, 215-225. http://dx.doi.org/10.1080/00365510601032532
Kusminski, C.M., McTernan, P.G. and Kumar, S. (2005) Role of Resistin in Obesity, Insulin Resistance and Type II Diabetes. Clinical Science, 109, 243-256. http://dx.doi.org/10.1042/CS20050078
Ouchi, N., Parker, J.L., Lugus, J.J. and Walsh, K. (2011) Adipokines in Inflammation and Metabolic Disease. Nature Reviews Immunology, 11, 85-97. http://dx.doi.org/10.1038/nri2921
Sahu, A. (2011) Intracellular Leptin-Signaling Pathways in Hypothalamic Neurons: The Emerging Role of Phosphatidylinositol-3 Kinase-Phosphodesterase-3 B-Camp Pathway. Neuroendocrinology, 93, 201-210. http://dx.doi.org/10.1159/000326785
Mataresse, G., La Cava, A., Sanna, V., Howard, J.K., Lord, G.M., Carravetta, C., Fontana, S., Lechler, R.I., Bloom, S.R. and De Placido, G. (2000) Increased Leptin Levels in Serum and Peritoneal Fluid of Patients with Pelvic Endometriosis. Journal of Clinical Endocrinology & Metabolism, 85, 2483-2487.
Reilly, M.P., Iqbal, N., Schutta, M., Wolfe, M.L., Scally, M., Localio, A.R., Rader, D.J. and Kimmel, S.E. (2004) Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism, 89, 3872-3878. http://dx.doi.org/10.1210/jc.2003-031676
Kamińska, A., Kopczyńska, E., Bronisz, A., Zmudzińska, M., Bieliński, M., Borkows, A., et al. (2010) An Evaluation of Visfatin Levels in Obese Subjects. Endokrynologia Polska, 61, 169-173.
Wannamethee, S.G., Tchernova, J., Whincup, P., Lowe, G.D., Kelly, A., Rumley, A., Wallace, A.M. and Sattar, N. (2007) Plasma Leptin: Associations with Metabolic, Inflammatory and Haemostatic Risk Factors for Cardiovascular Disease. Atherosclerosis, 191, 418-426. http://dx.doi.org/10.1016/j.atherosclerosis.2006.04.012
Stefanovic, A., Kotur-Stevuljevic, J., Spasic, S., Bogavac-Stanojevic, N. and Bujisic, N. (2008) The Influence of Obesity on the Oxidative Stress Status and the Concen-tration of Leptin in Type 2 Diabetes Mellitus Patients. Diabetes Research and Clinical Practice, 79, 156-163. http://dx.doi.org/10.1016/j.diabres.2007.07.019
Abdella, N.A., Mojiminiyi, O.A., Moussa, M.A., Zaki, M., Al Mohammedi, H., Al Ozairi, E.S. and Al Jebely, S. (2005) Plasma Leptin Concentration in Patients with Type 2 Diabetes: Relationship to Cardiovascular Disease Risk Factors and Insulin Resistance. Diabetic Medicine, 22, 278-285. http://dx.doi.org/10.1111/j.1464-5491.2004.01405.x
Asakawa, H., Tokunaga, K. and Kawakami, F. (2001) Relationship of Leptin Level with Metabolic Disorders and Hypertension in Japanese Type 2 Diabetes Mellitus Patients. Journal of Diabetes and its Complications, 15, 57-62. http://dx.doi.org/10.1016/S1056-8727(00)00145-8
Thorand, B., Zierer, A., Baumert, J., Meisinger, C., Herder, C. and Koenig, W. (2010) Associations between Leptin and the Leptin/Adiponectin Ratio and Incident Type 2 Diabetes in Middle-Aged Men and Women: Results from the MONICA/KORA Augsburg Study 1984-2002. Diabetic Medicine, 27, 1004-1011. http://dx.doi.org/10.1111/j.1464-5491.2010.03043.x
Maenhaut, N. and van de Voorde, J. (2011) Regulation of Vascular Tone by Adipocytes. BMC Medicine, 16, 9-25.
Snehalatha, C., Mukesh, B., Simon, M., Viswanathan, V., Haffner, S.M. and Ramachandran, A. (2003) Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indians. Diabetes Care, 26, 3226-3229. http://dx.doi.org/10.2337/diacare.26.12.3226
Li, S., Shin, H.J., Ding, E.L. and van Dam, R.M. (2009) Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis. The Journal of the American Medical Association, 302, 179-188. http://dx.doi.org/10.1001/jama.2009.976
Lautamaki, R., Ronnemaa, T., Huupponen, R., Lehtimaki, T., Iozzo, P., Airaksinen, K.E., Knuuti, J. and Nuutila, P. (2007) Low Serum Adiponectin Is Associated with High Circulating Oxidized Low-Density Lipoprotein in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. Metabolism, 56, 881-886. http://dx.doi.org/10.1016/j.metabol.2007.01.018
Matsuzawa, Y., Funahashi, T. and Nakamura, T. (1999) Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines Adipocyte-Derived Bioactive Substances. Annals of the New York Academy of Sciences, 892, 146-154.
Kern, P.A., Di Gregorio, G.B., Lu, T., Rassouli, N. and Ranganathan, G. (2003) Adiponectin Expression from Human Adipose Tissue: Relation to Obesity, Insulin Resistance, and Tumor Necrosis Factor-α Expression. Diabetes, 52, 1779-1785. http://dx.doi.org/10.2337/diabetes.52.7.1779
Okamoto, Y., Kihara, S., Ouchi, N., Nishida, M., Arita, Y., Kumada, M., Ohashi, K., Sakai, N., Shimomura, I., Kobayashi, H., Terasaka, N., Inaba, T., Funahashi, T. and Matsuzawa, Y. (2002) Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice. Circulation, 106, 2767-2770. http://dx.doi.org/10.1161/01.CIR.0000042707.50032.19
Spergel, J.M., Mizoguchi, E., Oettgen, H., Bhan, A.K. and Geha, R.S. (1999) Roles of TH1 and TH2 Cytokines in a Murine Model of Allergic Dermatitis. Journal of Clinical Investigation, 103, 1103-1111. http://dx.doi.org/10.1172/JCI5669
Dubucquoi, S., Desreumaux, P., Janin, A., Klein, O., Goldman, M., Tavernir, J., Capron, A. and Capron, M. (1994) Interleukin 5 Synthesis by Eosinophils Association with Granules and Immunoglobulin Dependent Secretion. Journal of Experimental Medicine, 179, 703-708. http://dx.doi.org/10.1084/jem.179.2.703
Matsuzawa, Y., Funashi, T., Kihara, S. and Shimomura, I. (2004) Adiponectin and Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 29-33. http://dx.doi.org/10.1161/01.ATV.0000099786.99623.EF
Trujillo, M.E. and Scherer, P.E. (2005) Adiponectin Journey from an Adipocyte Secretory Protein to Biomarker of the Metabolic Syndrome. Journal of Internal Medicine, 257, 167-175. http://dx.doi.org/10.1111/j.1365-2796.2004.01426.x
Halleux, C.N.M., Takahashi, M., Delporte, M.L., Detryc, R., Funahashi, T., Matsuzawa, Y. and Brichard, S.M. (2001) Secretion of Adiponectin and Regulation of apM1 Gene Expression in Human Visceral Adipose Tissue. Biochemical and Biophysical Research Communications, 288, 1102-1107. http://dx.doi.org/10.1006/bbrc.2001.5904
Nagaev, I. and Smith, U. (2001) Insulin Resistance and Type 2 Diabetes Are Not Related to Resistin Expression in Human Fat Cells or Skeletal Muscle. Biochemical and Biophysical Research Communications, 285, 561-564. http://dx.doi.org/10.1006/bbrc.2001.5173
Habib, S.S. (2012) Serum Resistin Levels in Patients with Type 2 Diabetes Mellitus and Its Relationship with Body Composition. Saudi Medical Journal, 33, 495-499.
Gharibeh, M.Y., Al Tawallbeh, G.M., Abboud, M.M., Radaideh, A., Alhader, A.A. and Khabour, O.F. (2010) Correlation of Plasma Resistin with Obesity and Insulin Resistance in Type 2 Diabetic Patients. Diabetes & Metabolism, 6, 443-449. http://dx.doi.org/10.1016/j.diabet.2010.05.003
Sommer, G., Garten, A., Petzold, S., Beck-Sickinger, A.G., Bluher, M., Stumvoll, M., et al. (2008) Visfatin/PBEF/Nampt: Structure, Regulation and Potential Function of a Novel Adipokine. Clinical Science, 115, 13-23.
Rego-Filho, E.A., Mello, S.F., Omuro, A.M. and Loli, J.O. (2003) Simultaneous Onset of Steroid-Sensitive Nephrotic Syndrome and Type 1 Diabetes. Jornal de Pediatria, 79, 557-560.
Mantzoros, C., Petridou, E., Dessypris, N., Chavelas, C., Dalamaga, M., Alexe, D.M., et al. (2004) Adiponectin and Breast Cancer Risk. Journal of Clinical Endocrinology & Metabolism, 89, 1102-1107. http://dx.doi.org/10.1210/jc.2003-031804